Acetylator phenotype in patients with lung carcinoma--a negative report

Eur J Respir Dis. 1985 Jul;67(1):17-9.

Abstract

Fractional acetylation of plasma sulphadimidine 6 h after dosing with 40 mg/kg metabolically active mass (p.o.) was measured in 53 patients with primary lung carcinoma and in 31 controls. Sixty percent of all tumour patients and 58% of controls were slow acetylators. There was no statistical evidence (P greater than 0.5) of association between acetylator phenotype and lung carcinoma.

MeSH terms

  • Acetylation
  • Acetyltransferases / genetics*
  • Aged
  • Arylamine N-Acetyltransferase / genetics*
  • Arylamine N-Acetyltransferase / metabolism
  • Carcinoma, Squamous Cell / blood
  • Carcinoma, Squamous Cell / enzymology
  • Carcinoma, Squamous Cell / genetics
  • Female
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / enzymology*
  • Lung Neoplasms / genetics
  • Male
  • Middle Aged
  • Phenotype
  • Sulfamethazine / blood

Substances

  • Sulfamethazine
  • Acetyltransferases
  • isoniazid acetyltransferase
  • Arylamine N-Acetyltransferase